ERAS and BBOT Related Headlines
Go Back- Oppenheimer on BridgeBio Oncology Therapeutics, In (BBOT): 'We think the lack of idiosyncratic toxicity is particularly notable for BBO-10203'
- Erasca, Inc (ERAS) Pulls Back from 20+pct Jump, Stifel: 'Today's Strength Driven by Competitor Readthrough'
